Co-Diagnostics, Inc. CODX
NASDAQ · United States · Health Technology
$1.080.00 (0.00%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Seth Egan, Chief Commercialization Officer, will represent the Company at two global health events during the 81st Session of the United Nations General Assembly in New York City:
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Seth Egan, Chief Commercialization Officer, will participate in the Global Health Technologies Coalition (GHTC) and Adjuvant Capital roundtable discussion on September 22, 2026, in New York, NY.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in the upcoming joint WHO/Unitaid/UNAIDS Annual Consultation Meeting. Joseph Featherstone, Executive Vice President of Business Development, will represent Co-Dx at the annual meeting, which will be held at the World Health Organization (WHO) headquarters in Geneva, Switzerland,
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.